![](/img/cover-not-exists.png)
PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN PORTUGAL: A COMPARISON OF BEVACIZUMAB IN COMBINATION WITH INTERFERON ALFA-2A AND SUNITINIB
CI Silva, I Monteiro, B SchwanderVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71936-2
File:
PDF, 76 KB
english, 2010